Menu

Onkologia - aktualności medyczne dla lekarzy

esmo logo

The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours

16.04.2021

A new web-based calculator based on the results of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update analysis allows improved and more granular individual prognostic assessment in patients with metastatic non-seminomatous germ cell tumours (NSGCT) and can help to shape strategies for future clinical trials.

baner webinarium „Zabiegi cytoredukcyjne i HIPEC w leczeniu chorych z nowotworami otrzewnej”

Zabiegi CRS i HIPEC w leczeniu chorych z nowotworami otrzewnej - pełny materiał z webinarium

16.04.2021

Udostępniamy Państwu pełny materiał z webinarium poświęconego leczeniu chorych z pierwotnymi i wtórnymi (przerzutowymi) nowotworami otrzewnej. Mamy nadzieję, wspólnie z autorami wszystkich wykładów, że przedstawione przykłady przyczynią się do częstszego leczenia nowotworów otrzewnej metodą CRS + HIPEC.

asco logo

Screening for Targetable FGFR Mutations From a Community Practice Perspective

15.04.2021

In clinical oncology, fibroblast growth factor receptor (FGFR) screening usually refers to testing a patient's tumor tissue for activating DNA mutations in the FGFR2 or FGFR3 gene that can potentially be targeted with a FDA – approved FGFR inhibitor.

esmo logo

Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time

15.04.2021

A new analysis from US show that response to genome-targeted therapy increased from 2.73% in 2006 to 7.04% in 2020. Most of the increase in response was seen prior to 2018, and most of the increase in eligibility after 2018.

asco logo

Using Molecular Testing in Small Cell Lung Cancer, Potential Implications for Treatment

14.04.2021

Although impressive progress has been made on the non–small cell lung cancer (NSCLC) landscape, with U.S. Food and Drug Administration (FDA)–approved therapies for a multitude of molecular alterations, the advancements in small cell lung cancer (SCLC) have been less robust.

esmo logo

FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer

14.04.2021

On 13 April 2021, the FDA granted accelerated approval to sacituzumab govitecan for patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.

baner Konferencji Debaty Rak Prostaty 2021

Konferencja „Debaty Rak Prostaty” 2021

14.04.2021

Zapraszamy serdecznie w imieniu organizatorów na Konferencję „Debaty Rak Prostaty”, która odbędzie się 22.05.2021 roku (sobota), w trybie online. Wydarzenie kierowane jest do urologów, onkologów, radioterapeutów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką.

baner Konferencji “Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej 2021

Konferencja „Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej” 2021

14.04.2021

W imieniu organizatorów serdecznie zapraszamy na interdyscyplinarną konferencję naukową “Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej”. Celem wydarzenia jest poszerzenie wiedzy z zakresu diagnostyki genetycznej oraz onkohematologii.

esmo logo

FDA Approves New Dosing Regimen for Cetuximab

13.04.2021

On 6 April 2021, the FDA approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab for patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN).

nccn logo

Important Potential Role for Routine Brain Imaging in Advanced Kidney Cancer

13.04.2021

Journal of the National Comprehensive Cancer Network publishes new research which suggests that baseline brain imaging should be considered in most patients with metastatic kidney cancer. Study finds 4% of patients with metastatic renal cell carcinoma developed asymptomatic brain metastases, which correlated to poorer outcomes.

logotyp Agencji Oceny Technologii Medycznych i Taryfikacji

Pozytywna opinia AOTMiT dotycząca refundacji olaparybu w leczeniu raka jajnika, jajowodów i otrzewnej

13.04.2021

6 kwietnia 2021 roku Rada Przejrzystości przy AOTMiT wydała pozytywną opinię w sprawie objęcia refundacją leków zawierających substancję czynną olaparibum w zakresie terapii podtrzymującej u pacjentów z zaawansowanym rakiem jajnika, jajowodu lub otrzewnej.

esmo logo

FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer

12.04.2021

On 7 April 2021, the FDA granted regular approval to sacituzumab govitecan for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

esso logo

Guidelines on clinical nutrition in cancer

11.04.2021

The European Society for Clinical Nutrition and Metabolism (ESPEN) launched its guideline on clinical nutrition in cancer as an app version for smartphones and tablets. The app is available for download for iOS and Android. A web-based version is available at guidelines.espen.org for free.

esmo logo

Textbook of Pancreatic Cancer Principles & Practice of Surgical Oncology

10.04.2021

This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients.

aacr logo

Copanlisib-Rituximab Combination Cuts Lymphoma Progression or Death by Nearly Half in CHRONOS-3 Trial

10.04.2021

A combination of copanlisib and rituximab led to a 48 percent reduction in the risk of disease progression or death compared with placebo and rituximab in patients with relapsed indolent non-Hodgkin lymphoma, according to data from the phase III trial CHRONOS-3, presented during Week 1 of the virtual AACR Annual Meeting 2021.

aacr logo

Healthy Lifestyle May Offset Risk of Lethal Prostate Cancer in Men With High Genetic Risk

10.04.2021

Men who had a high genetic risk of developing prostate cancer were less likely to develop a lethal form of the disease if they maintained a healthy lifestyle, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021.

aacr logo

Liquid Biopsy Augments MRI for Predicting Response to Neoadjuvant Treatment in Patients With Breast Cancer

10.04.2021

A liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic resonance imaging (MRI) for predicting the achievement of complete response among patients with locally advanced breast cancer who had received neoadjuvant chemotherapy, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021.

aacr logo

Personalized Cancer Vaccine Given After Adjuvant Therapy Safe, Shows Early Efficacy in Multiple Tumor Types

10.04.2021

Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and showed potential clinical benefit in patients with diverse tumor types with high risk of recurrence, according to results from a phase I clinical trial presented during Week 1 of the virtual AACR Annual Meeting 2021.

aacr logo

Unselected Autologous Tumor Infiltrating Lymphocyte Therapy Shows Early Promise in Patients With Metastatic Melanoma

10.04.2021

Treatment with unselected autologous tumor infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021.

aacr logo

Bispecific Fusion Protein Tebentafusp Significantly Improves Overall Survival in Patients With Metastatic Uveal Melanoma

10.04.2021

Compared with available standard therapies, including immune checkpoint inhibitors, treatment with the bispecific fusion protein tebentafusp nearly halved the risk of death among patients with metastatic uveal melanoma, according to results of a phase III clinical trial presented during Week 1 of the virtual AACR Annual Meeting 2021.

aacr logo

Neoadjuvant Nivolumab plus Chemotherapy Increased Pathological Complete Response Rate in CheckMate-816 Lung Cancer Trial

10.04.2021

Adding nivolumab to chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) produced significant improvement of pathological complete response rate to 24 percent, compared with 2.2 percent in the chemotherapy alone arm, with the combination treatment leading to no increase in overall toxicity or delays to surgery, according to data from the phase III trial CheckMate-816, presented during Week 1 of the virtual AACR Annual Meeting 2021.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Duvelisib

09.04.2021

On 25 March 2021, the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product duvelisib, intended for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL).

esmo logo

Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal Cancer in FAP

08.04.2021

Japanese researchers reported on 1 April 2021 in The Lancet Gastroenterology & Hepatology findings from a randomised, double-blind, placebo-controlled study with a two-by-two factorial design, conducted in 11 centres, that low-dose aspirin safely suppressed the recurrence of colorectal polyps larger than 5 mm in patients with familial adenomatous polyposis (FAP).

asco logo

Incorporating PARP Inhibitors Into the Pancreatic Cancer Treatment Armamentarium

08.04.2021

PARP inhibitors are a potential effective treatment option for patients with BRCA-associated cancers, including pancreatic adenocarcinoma (PDAC). The POLO study was the first biomarker-driven phase III trial to show an improvement in progression-free survival in PDAC.

esso logo

The value of surgical oncology in the management of cancer patients

08.04.2021

Surgery is a key component of cancer care and 80% of cancer patients will require some form of surgical intervention during the course of their disease. It is estimated that by the year 2030, 45 million surgical procedures will be required. Additionally, in some less-developed regions of the world, surgery may be the only viable treatment option for several reasons.

esmo logo

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma

07.04.2021

On 26 March 2021, FDA approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.

asco logo

Can Biomarkers Guide the Management of Sarcomas?

07.04.2021

Sarcomas need biomarkers perhaps more than any other group of malignancies due to their unpredictability, controversy around systemic therapy, and questions surrounding patient selection for immunotherapy.

eco logo

The Cancer Workforce: The Key to Unlocking the Promise of Europe’s Beating Cancer Plan

07.04.2021

Ahead of a meeting today with the EU Commissioner for Health and Food Safety, the European Cancer Organisation (E.C.O.) has published a new consensus paper conveying the critical challenges for the cancer workforce in the context of implementing Europe’s Beating Cancer Plan.

esmo logo

Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal Junction Cancer

06.04.2021

In CheckMate 577 study conducted among patients with resected oesophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab was associated with a significantly longer disease-free survival (DFS) than placebo.

estro logo

Focal Boost to the Intraprostatic Tumour in External Beam Radiotherapy for Patients With Localised Prostate Cancer

06.04.2021

This study investigates whether focal boosting of the macroscopic visible tumour with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localised prostate cancer.

logotyp Polskiego Towarzystwa Chirurgii Onkologicznej

Wytyczne PTChO dla chirurgów i dermatologów dotyczące diagnozowania czerniaków

06.04.2021

Polskie Towarzystwo Chirurgii Onkologicznej, Sekcja Onkologiczna Polskiego Towarzystwa Dermatologicznego oraz Polskie Towarzystwo Patologów opracowało wspólnie kartę-drogowskaz „Pacjent ze zmianą barwnikową. Postępowanie diagnostyczne dla dermatologów i chirurgów wraz z kartą konsultacyjną pacjenta”.

esmo logo

EMA Recommends Extension of Indications for Enzalutamide

02.04.2021

On 25 March 2021, European Medicines Agency’s adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product enzalutamide. New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.

logo Narodowego Instytutu Onkologii oraz National Comprehensive Cancer Network

NCCN będzie współpracować z specjalistami z Polski w zakresie tworzenia polskich zaleceń postępowania diagnostyczno-terapeutycznego w onkologii

02.04.2021

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, National Comprehensive Cancer Network i Alliance for Innovation podpisały umowę o współpracy, dzięki której eksperci z NCCN podzielą się swoją wiedzą i międzynarodowym doświadczeniem w opracowaniu zaleceń postępowania diagnostyczno-terapeutycznego w onkologii.

baner webinarium „Zabiegi cytoredukcyjne i HIPEC w leczeniu chorych z nowotworami otrzewnej”

Zaproszenie na webinarium „Zabiegi cytoredukcyjne i HIPEC w leczeniu chorych z nowotworami otrzewnej”

01.04.2021

Zapraszam Państwa na Webinarium poświęcone leczeniu chorych z pierwotnymi i wtórnymi (przerzuty) nowotworami otrzewnej. Prezentacje będą miały formę omówienia leczenia wybranych przypadków medycznych „case reports” - dr hab. n. med. Tomasz jastrzębski, prof. nadzw.

asco logo

Combination Immunotherapy and BRAF/MEK Inhibitor Therapy for BRAFV600-Mutated Advanced Melanoma: Are We There Yet?

01.04.2021

Triplet therapy provides a new treatment option for patients with advanced BRAF-mutated melanoma, but is limited by the lack of survival benefit and increased toxicity.

esmo logo

Delayed irAEs Occur in a Small Subset of Patients with Melanoma, but Often High Grade and Difficult to Manage

01.04.2021

An analysis published on 30 March 2021 in the Annals of Oncology, shows that delayed immune-related adverse events (irAEs) occur in a small subset of patients with melanoma. However, delayed irAEs are often high grade and difficult to manage, frequently requiring extended course of systemic corticosteroids or additional immunosuppression and can lead to death.

asco logo

The Impact of Adjuvant Osimertinib in Resectable Non–Small Cell Lung Cancer

31.03.2021

The ADAURA trial showed a 46% absolute risk reduction of recurrence at 2 years with osimertinib, but the trial has several limitations, including disease-free survival as a surrogate endpoint.

esmo logo

Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in Hypermutated Tumours

31.03.2021

An analysis based on a review of the recent FDA approval of pembrolizumab in patients with treatment-refractory cancers and a tumour mutational burden (TMB) greater than 10 mutations per megabase, found that the overall survival (OS) benefit was decreased in several tumour types and after re-evaluation according to stratification by other criteria.

astro logo

COVID-19 pandemic has led to more advanced-stage cancer diagnoses, physician survey finds

30.03.2021

Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanced disease than before the COVID-19 pandemic, according to a new survey from the American Society for Radiation Oncology (ASTRO).

esmo logo

FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma

30.03.2021

FDA approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced oesophageal or gastro-oesophageal (tumours with epicenter 1 to 5 centimeters above the gastro-oesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.

baner Konferencji “Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej 2021

Konferencja „Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej” 2021

30.03.2021

W imieniu organizatorów serdecznie zapraszamy na interdyscyplinarną konferencję naukową “Wyzwania współczesnej diagnostyki genetycznej i onkohematologii dziecięcej”. Celem wydarzenia jest poszerzenie wiedzy z zakresu diagnostyki genetycznej oraz onkohematologii.

estro logo

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer

29.03.2021

We report the clinical outcomes of a randomised trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. Prophylactic pelvic irradiation for high-risk, locally advanced prostate cancer improved BFFS and DFS as compared with PORT, but OS did not appear to differ.

esmo logo

EMA Recommends Extension of Indications for Atezolizumab

29.03.2021

New indication concerns first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression.

esmo logo

Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in Patients with Early Stage NSCLC

27.03.2021

Results from the ASTEROID study with durvalumab after stereotactic body radiotherapy in patients with early stage non-small cell lung cancer.

aacr logo

Mutations in Circulating Tumor Cells May Predict Clinical Outcomes in Patients with Metastatic Castrate-resistant Prostate Cancer

26.03.2021

Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research, a journal of the American Association for Cancer Research.

esmo logo

Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer

26.03.2021

Despite sound rationale that patients with platinum sensitive non-small cell lung cancer (NSCLC) should also be sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi), olaparib maintenance did not improve survival in a small under-enrolled phase II study. These findings were presented at the European Lung Cancer Virtual Congress 2021.

baner Konferencji Debaty Rak Nerki 2021

Konferencja „Debaty Rak Nerki” 2021

26.03.2021

Zapraszamy w imieniu organizatorów na Konferencję „Debaty Rak Nerki”, która odbędzie się 24 kwietnia 2021 roku (sobota), w trybie online. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, radioterapeutów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką.

esmo logo

Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer

25.03.2021

Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021.

esmo logo

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

25.03.2021

Updated results from the phase III KEYNOTE-407 study reported at the European Lung Cancer Virtual Congress 2021 demonstrated that survival and response rates remained improved with pembrolizumab plus chemotherapy over placebo plus chemotherapy in treatment-naive patients with metastatic squamous non-small cell lung cancer (NSCLC).

esmo logo

Rise in Brain Metastases Detected in Patients with Stage IV NSCLC During COVID-19 Pandemic

24.03.2021

Computed tomography (CT) and/or magnetic resonance imaging (MRI) demonstrated that 39% of patients diagnosed with stage IV non-small cell lung cancer (NSCLC) presented with de novo brain metastases during the COVID-19 pandemic, higher than historic rates, and many of these patients were asymptomatic for brain metastases.

esmo logo

Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined

24.03.2021

A large comprehensive analysis of patient-specific alterations of the anaplastic lymphoma kinase (ALK) gene occurring in non-small cell lung cancer (NSCLC) reported at the European Lung Cancer Virtual Congress 2021 provided additional insight into the landscape of ALK alterations that may guide treatment of NSCLC.

esmo logo

Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway

24.03.2021

A retrospective analysis of patients with non-small cell lung cancer (NSCLC) identified potentially targetable alterations in the phosphoinositide-3-kinase (PI3K) pathway that were not mutually exclusive to mutations in other pathways, according to findings presented at the European Lung Cancer Virtual Congress 2021.

esmo logo

Determination of the Incidence of Driver Mutations in Patients with NSCLC and Brain Metastases

24.03.2021

The incidence of brain metastasis at diagnosis in patients with non-small cell lung cancer (NSCLC) harbouring driver mutations was high, according to findings presented at the European Lung Cancer Virtual Congress 2021. However, these patients achieved similar outcomes with treatment as patients without brain metastases.

asco logo

Rising Importance of CAR T-cell Therapies for Multiple Myeloma

24.03.2021

CAR T-cell therapies are cultivating new and promising care approaches for patients with multiple myeloma. Many hematologic malignancies, including myeloma, are currently incurable and linked to low overall survival rates. CAR T-cell interventions may continue improving treatment plans, symptom management, and health outcomes in the multiple myeloma space.

asco logo

Multidisciplinary Treatment of Patients With Non–Small Cell Lung Cancer and Brain Metastases

24.03.2021

Between 10% and 15% of patients with non–small cell lung cancer (NSCLC) have brain metastases at the time of diagnosis, with some 25% to 50% developing intracranial disease over their disease course, representing nearly half of all patients with central nervous system (CNS) metastases. The incidence is expected to increase as survival in advanced NSCLC continues to improve.

logo wydarzenia „Wejrzenie w nowotworzenie”

X Ogólnopolska Konferencja Naukowa „Wejrzenie w nowotworzenie”

24.03.2021

W imieniu organizatorów mamy przyjemność zaprosić na X Edycję Ogólnopolskiej Konferencji Naukowej „Wejrzenie w nowotworzenie”. Jej celem jest przybliżenie uczestnikom mechanizmów molekularnych odpowiedzialnych za powstawanie chorób nowotworowych, a także prezentacja postępów w ich diagnostyce i leczeniu.

European Cancer Organisation logo

Eliminating HPV-Caused Cancers in Europe: Achieving the Possible

23.03.2021

The 690,000 cases of cancer caused worldwide each year by HPV (human papillomavirus) are among the easiest of all cancers to prevent. However, the actions so far taken in terms of both policy and practice by health systems in many European states have neither matched the scale of the problem nor seized the opportunities for disease prevention potentially offered by vaccination and screening.

eortc logo

Surviving glioblastoma? EORTC Brain Tumour Group explores the factors that contribute to long-term survival

23.03.2021

Glioblastomas represent almost 50% of malignant primary brain tumors in adults, and range among the most lethal cancer types. Approximately three in 100,000 people a year are diagnosed with a glioblastoma. Due to the aggressive nature of this tumor, which invades the brain by infiltration and destroys healthy brain tissue, glioblastomas lead to a significantly reduced life span.

baner webinarium „Zabiegi cytoredukcyjne i HIPEC w leczeniu chorych z nowotworami otrzewnej”

Zabiegi cytoredukcyjne i HIPEC w leczeniu chorych z nowotworami otrzewnej

22.03.2021

Zapraszamy na webinarium poświęcone leczeniu chorych z pierwotnymi i wtórnymi (przerzuty) nowotworami otrzewnej. Prezentacje będą miały formę omówienia leczenia wybranych przypadków medycznych („case reports”), obejmujących śluzaka rzekomego otrzewnej, przerzuty do otrzewnej raka żołądka, raka jajnika, raka jelita grubego a także nowotworów wieku dziecięcego.

esmo logo

Factors Associated with COVID-19 Severity Among Patients with Cancer

22.03.2021

Better understanding of specific risk factors associated with poor COVID-19 outcomes may help guide clinical management in these patients. Leveraging detailed information from almost 5,000 cancer patients with COVID-19, researchers from an international CCC19 consortium evaluated the hypothesis that specific demographic characteristics, clinical factors, and laboratory measurements are associated with severity of COVID-19.

nice logo

Triple therapy recommended by NICE for patients with multiple myeloma

22.03.2021

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma after NICE recommended its use. Clinical trial evidence shows that carfilzomib with lenalidomide and dexamethasone gives longer periods of remission and people live longer, compared with the current second line treatment lenalidomide plus dexamethasone.

esmo logo

FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

18.03.2021

On 5 March 2021, the US Food and Drug Administration (FDA) granted accelerated approval to axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Approval in FL was based on a single-arm, open-label, multicentre study (ZUMA-5; NCT03105336).

esmo logo

High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint Inhibitors Across All Cancer Types

17.03.2021

According to a group of researchers led by Dr Daniel McGrail of MD Anderson Cancer Center in Houston, TX, US, who analyzed data from patient tumours included in The Cancer Genome Atlas (TCGA), their analysis failed to support the use of high tumour mutation burden (TMB-H) as a biomarker for treatment with immune checkpoint inhibitors (ICIs) in all tumour types.

asco logo

Data from ESMO, GU Cancers Symposium Highlight Progress in Kidney Cancer Treatment

17.03.2021

Treatment for advanced kidney cancer has undergone an impressive improvement in recent years due to the development of targeted therapies against VEGF, a key driver of angiogenesis, or mTOR pathways and immunotherapy. Those treatments have been sequentially offered to patients demonstrating an increase in overall survival (OS).

esmo logo

EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions for Infusion Continue to Outweigh Risks

16.03.2021

The European Medicines Agency (EMA) announced on 12 March 2021 that its Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefits of ifosfamide solutions for infusion continue to outweigh their risks in the treatment of different types of cancers, including various solid tumours and lymphomas.

estro logo

Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC)

16.03.2021

Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision.

esmo logo

Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell Lung Cancer

15.03.2021

In an updated integrated analysis of three phase I or II clinical studies ALKA-372-001, STARTRK-1, and STARTRK-2, comprising more patients and a longer follow-up than the primary analysis, entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion–positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

eortc logo

Long-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy

13.03.2021

The decision on whether or not to give chemotherapy after breast cancer surgery is always a difficult one. Because the treatment can have serious side effects, some of them long-term, there is sometimes a risk that its use may do more harm than good. The MINDACT (EORTC 10041/BIG3-04) study, a multicentre, randomised phase 3 clinical trial, aimed to provide an answer to this question.

esmo logo

FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma

12.03.2021

On 10 March 2021, the US Food and Drug Administration (FDA) approved tivozanib, a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

esso logo

Textbook of Pancreatic Cancer Principles & Practice of Surgical Oncology

11.03.2021

This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients.

nccn logo

NCCN Provides New COVID-19 Treatment Advice; Updates Vaccine Guidance for Cancer Patients

11.03.2021

Leading cancer and infectious disease experts analyze latest data and FDA approvals to create evidence-based expert consensus recommendations for both treatment and prevention of COVID-19 for people with cancer.

esmo logo

Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with AML or MDS

11.03.2021

Clinical utility of whole-genome sequencing demonstrated for the genomic evaluation of patients with acute myeloid leukaemia or myelodysplastic syndromes.

logo Polskiego Towarzystwa Ginekologii Onkologicznej

Stanowisko PTGO w sprawie chirurgii małoinwazyjnej w leczeniu nowotworów szyjki i trzonu macicy

11.03.2021

Zarząd Polskiego Towarzystwa Ginekologii Onkologicznej uważa, że korzyści z małoinwazyjnej chirurgii w porównaniu z laparotomią w przypadku nowotworów trzonu macicy są oczywiste i uzasadniają wybór tej formy terapii jako metody z wyboru. Zastosowanie chirurgii laparoskopowej czy robotowej, u chorych na raka szyjki macicy powinna być szeroko wykorzystywana jedynie w ramach badań klinicznych lub guzów o średnicy do 2 cm.

baner konferencji Urologia post COVID-19

Konferencja „Urologia post COVID-19”

10.03.2021

Konferencja „Urologia post COVID-19” odbędzie się 20.03.2021 roku (sobota), w trybie online. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, radiologów, ginekologów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką. Podczas wydarzenia omówione zostaną między innymi: wnioski z analizy opóźnień w wykonywaniu zabiegów operacyjnych.

esmo logo

FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer

10.03.2021

On 3 March 2021, the US Food and Drug Administration (FDA) granted regular approval to lorlatinib for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, detected by an FDA-approved test.

asco logo

Exploring the Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma

10.03.2021

Immune checkpoint inhibitors (ICIs) are the standard of care for eligible patients with mRCC. However, a significant number of patients will not benefit from the initial ICI treatment because of primary resistance, and some will relapse after a period of response, a state known as acquired or secondary resistance.

asco logo

Precision Medicine Driving Progress in the Treatment of Gastrointestinal Cancers

10.03.2021

Molecular profiling in the field of gastrointestinal (GI) cancers is precision medicine at its finest, according to physician-scientist Rachna T. Shroff, MD, MS, chief of GI Medical Oncology at the University of Arizona Cancer Center and member of the ASCO Daily News Expert Panel.

esmo logo

NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses in Operable NSCLC

09.03.2021

Findings from the randomised phase II NEOSTAR study indicate that neoadjuvant treatment with nivolumab plus ipilimumab enhances pathologic responses, tumour immune infiltrates and immunologic memory in patients with operable non-small cell lung cancer (NSCLC).

nccn logo

New Evidence on Need to Address Muscle Health among Patients with Cancer

09.03.2021

Results of new study from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the Treatment of Metastatic Prostate Cancer

08.03.2021

On 25 February 2021, the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Abiraterone Accord, intended for the treatment of metastatic prostate cancer.

esso logo

Guidelines on clinical nutrition in cancer

08.03.2021

The European Society for Clinical Nutrition and Metabolism (ESPEN) launched its guideline on clinical nutrition in cancer as an app version for smartphones and tablets. The app is available for download for iOS and Android. A web-based version is available at guidelines.espen.org for free.

esmo logo

Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated Advanced RCC

05.03.2021

In CheckMate 9ER study among patients with previously untreated advanced renal-cell carcinoma (RCC), nivolumab plus cabozantinib had significant benefits over sunitinib in terms of progression-free survival (PFS), overall survival (OS), and the likelihood of objective response.

aacr logo

Ambulatory Function Among Cancer Survivors May be an Important Determinant for Survival

04.03.2021

Cancer survivors had a greater risk of reduced ambulatory function, which was associated with an increased risk of death, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab

04.03.2021

Combination of cabozantinib and nivolumab is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma

asco logo

Novel Therapies Advance the Field of Genitourinary Cancers

03.03.2021

Novel approaches to treating prostate and bladder cancers are renewing hope for patients with genitourinary (GU) malignancies. At the same time, the field is being further energized by the recent U.S. Food and Drug Administration (FDA) approval of several new agents.

esmo logo

Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in Patients With Refractory and Relapsed Multiple Myeloma

03.03.2021

Idecabtagene vicleucel, a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy induced responses in a majority of heavily pretreated patients with refractory and relapsed multiple myeloma.

asco logo

Defining and Identifying Patients at High-Risk for Breast Cancer

03.03.2021

Despite improvements in treatment and early detection, the incidence of breast cancer is rising, with prevention of modifiable risk factors remaining the best strategy for reducing mortality.

esmo logo

Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small Cell Lung Cancer

02.03.2021

Twice daily poziotinib dosing improved the adverse event profile; early results showed retained anti-tumour activity.

esmo logo

Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with FGFR Amplifications

02.03.2021

Clinical benefit of FGFR inhibition is stronger in patients with an FGFR fusion or mutation compared to FGFR amplification.

esmo logo

Tumour Signatures Defined by Next Generation Sequencing Are Linked to Clinical Response in Breast Cancer

02.03.2021

Endogenous and exogenous mutational processes driven by abnormal DNA editing, mutagens or age-related DNA alterations over the history of a malignant tumour provide an individual tumour signature

esmo logo

Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours

01.03.2021

Prelliminary data with IL-12 mRNA administered by intratumoural injection in combination with intravenous durvalumab

esmo logo

The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be Elevated in Patients with Autoimmune Disease

01.03.2021

Many cancer patients with autoimmune disease are excluded from studies of immune checkpoint inhibitors due to hypothesis of the association of this treatment with immune-related adverse events.

esmo logo

PD-L1 mRNA Baseline Expression May Indicate Response to Atezolizumab Plus Nab-paclitaxel in TNBC

01.03.2021

The patterns of PD-L1 mRNA expression in plasma-derived exosomes at baseline corresponded to response to atezolizumab plus nab-paclitaxel and survival in patients with triple negative breast cancer

esmo logo

Characterisation of Toxicity Profiles of Immune and Molecularly Targeted Agents in Phase I and II Studies

01.03.2021

Overall, more adverse events were reported with targeted therapies than with immunotherapy.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab

26.02.2021

It is intended for the treatment of recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.

asco logo

Exploring the Role of CDK4/6 Inhibitors in Early Breast Cancer

25.02.2021

The efficacy of CDK4/6 inhibitors in combination with standard endocrine therapy for HR+/HER2−negative early breast cancer has been actively explored in several clinical trials, including monarchE, PALLAS, and PENELOPE-B.

asco logo

ASCO Issues Guideline on Dyspnea in Advanced Cancer

25.02.2021

ASCO has issued a new guideline on the clinical management of dyspnea in adult patients with advanced cancer.1 Dyspnea—or breathlessness—is a common and distressing symptom affecting upwards of 70% of patients with advanced cancer.

asco logo

Role of Locoregional Therapy When Treating De Novo Advanced Breast Cancer

25.02.2021

Advanced breast cancer, defined for the purposes of this discussion as breast cancer that has spread to distant metastatic sites, is generally understood to be an incurable condition. Patients are, however, often curious about the role of breast surgery in the management of their cancer.

esmo logo

Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST

24.02.2021

After 9.1 years of follow-up, a trend toward better long-term imatinib failure-free survival in imatinib treated patients was observed in high-risk subgroup.

esmo logo

FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High PD-L1 Expression

23.02.2021

Approval concerns the treatment of patients with tumours without EGFR, ALK or ROS1 aberrations.

esmo logo

Five-Year Outcomes with CAR T Cell Therapy

22.02.2021

Tisagenlecleucel outcomes in relapsed or refractory DLBCL and follicular lymphoma.

esmo logo

EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the Gene Therapy

19.02.2021

As part of its advice on safety-related aspects to other European Medicines Agency (EMA) committees, the Pharmacovigilance Risk Assessment Committee (PRAC) discussed important safety information for Strimvelis, Venclyxto and Zolgensma.

asco logo

What TRAIN-2 Tells Us About Treating HER2-Positive Breast Cancer

17.02.2021

Amplification of HER2 is seen in approximately 15% to 20% of breast cancers and was associated with an inferior prognosis until the introduction of HER2-targeted therapies.1 Since then, disease-related outcomes such as disease-free survival (DFS), progression-free survival (PFS), and OS have improved remarkably.

esmo logo

Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6 Years Median Follow-Up in the APHINITY Study

17.02.2021

Cardiac safety is confirmed with longer follow-up after adjuvant dual anti-HER2 treatment for node-positive, HER2-positive early breast cancer.

asco logo

ASCO and Ontario Health Publish Joint Update on Guideline for Targeted Therapy in NSCLC With Driver Alterations

17.02.2021

ASCO and Ontario Health (Cancer Care Ontario) have jointly published an update1 to the 2017 ASCO guideline2 regarding systemic therapy recommendations for stage IV non–small cell lung cancer (NSCLC) with driver alterations.

esmo logo

pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage III Melanoma

16.02.2021

The International Neoadjuvant Melanoma Consortium reported the results of a pooled analysis that aimed to determine the relationship between pathological complete response (pCR) and clinical outcomes with neoadjuvant anti-PD1 immunotherapy and BRAF/MEK targeted therapy in patients with clinical stage III melanoma.

asco logo

RxPONDER Trial Data Changes Practice for Select Postmenopausal Patients with Breast Cancer

16.02.2021

The Oncotype DX recurrence score (RS) has been shown to provide both predictive information about the potential benefit of chemotherapy as well as prognostic information about recurrence risk.

asco logo

Neoadjuvant Therapy for Pancreatic Cancer: An Optimal Management Approach for All Stages That Needs Further Prospective and Randomized Evaluation

16.02.2021

Recent advances in the treatment of pancreatic adenocarcinoma (PAC) have improved the overall survival (OS) of patients with all stages of disease.1 However, despite curative intent treatment, the majority of patients experience recurrence. An improved understanding of the patterns of recurrence and strategies to mitigate local, regional, and distant recurrence will help maximize OS.

asco logo

Incorporating Immune Checkpoint Inhibitors Into the Treatment of EGFR ex20ins NSCLC Tumors

11.02.2021

What is the role of immunotherapy in treating non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations?

esmo logo

Breast Cancer Risk Genes

10.02.2021

Two large case–control studies provide important information on the risk of breast cancer and cancer types that is associated with several genes and their variants

asco logo

Treating Ovarian Cancer With Maintenance PARPi Therapy

10.02.2021

Based on results from the SOLO2/ENGOT-ov21 trial, could maintenance PARP inhibitor (PARPi) therapy ever be safely discontinued in patients with relapsed ovarian cancer and a BRCA mutation?

asco logo

Treating EGFR-Mutant Advanced Lung Cancer With Acquired Resistance

10.02.2021

In patients with EGFR-mutant advanced lung cancer who have developed acquired resistance to EGFR tyrosine kinase inhibitors (TKIs), could chemotherapy plus a TKI with stereotactic body radiotherapy (SBRT) be used for persistent lesions?

UCLA Health - logo

Obiecujące wyniki badań nad radioterapią skojarzoną ze środkami farmaceutycznymi nadzieją dla chorych na glejaka

10.02.2021

Glejak wielopostaciowy jest jednym z najbardziej śmiertelnych i najtrudniejszych do leczenia nowotworów mózgu. Radioterapia jest częścią standardowego schematu leczenia glejaka wielopostaciowego i często pomaga przedłużyć czas przeżycia pacjentów. Jednak pomimo postępów w medycynie czas przeżycia pacjentów z glejakiem nie poprawił się znacząco w ciągu ostatnich dwóch dekad.

esmo logo

Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides Targeted Therapy Information

09.02.2021

Using the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) investigators were able to rank the level of evidence of recurrent actionable molecular alterations found in head and neck squamous cell carcinoma (HNSCC) to aid in the prioritisation of treatment.

asco logo

PROfound Shows Significant Antitumor Activity With Olaparib for mCRPC in Patients With DNA Repair Mutations

08.02.2021

An updated gene-by-gene analysis of DNA repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III PROfound study found that patients with BRCA alterations had the most significant antitumor activity on olaparib , highlighting the potential overall survival (OS) benefit of genetic testing for all patients with high-risk mCRPC.

asco logo

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic

08.02.2021

ModraDoc006, a novel oral docetaxel formulation, has advantages as a convenient, oral, and better-tolerated potential therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) when combined with ritonavir.

asco logo

CheckMate-9ER: Patient-Reported Outcomes Show Significantly Improved Quality-of-Life Benefit of Novel Doublet for Advanced Renal Cell Carcinoma

08.02.2021

The CheckMate-9ER phase III trial revealed significantly improved patient-reported quality-of-life outcomes with first-line nivolumab plus cabozantinib compared to sunitinib for patients with advanced renal cell carcinoma (RCC), potentially matching the superior clinical efficacy of the novel doublet.

asco logo

Circulating Tumor DNA Detects Temporal Changes to mRCC Genetic Profile

08.02.2021

Circulating tumor DNA (ctDNA) and tissue-based genomic profiling had high levels of agreement in patients with metastatic renal cell carcinoma (mRCC), according to a new study to be presented during the 2021 Genitourinary Cancers Symposium (Abstract 347). Furthermore, ctDNA can detect changes to genomic profiles over time and potentially help guide treatment.

esmo logo

EMA Recommends Extension of Indications for Pembrolizumab

08.02.2021

On 28 January 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product pembrolizumab (Keytruda).

asco logo

Liquid Biopsy Offers Alternative for Comprehensive Genomic Profiling in Advanced Prostate Cancer

08.02.2021

Two new studies to be presented during the 2021 Genitourinary Cancers Symposium demonstrate the utility of genomic analysis of circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in advanced prostate cancer, offering noninvasive methods to identify targetable genetic mutations and thus potentially guide treatment with PARP inhibition.

esmo logo

FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC

05.02.2021

On 3 February 2021, the US Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

asco logo

Incorporating MRI–Guided Linear Accelerator Technology Into Radiation Therapy For Pancreatic Cancer

04.02.2021

Importantly, although the MR-LINAC may result in more precise (and safer) and higher-dose radiation plans, what ultimately matters is demonstrated improvement in clinical outcomes. Single institutional series from early MR-LINAC adopters show promising results regarding survival and toxicity rates,9-11 and there is now an open multi-institutional prospective trial: Stereotactic MRI–guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer.

esmo logo

Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab

04.02.2021

The European Medicines Agency (EMA) announced on 29 January 2021 that Roche Registration GmbH withdrew its application for the use of atezolizumab (Tecentriq) to treat metastatic urothelial cancer in combination with platinum-based therapy in patients who had not been treated before. The company withdrew the application on 8 January 2021.

asco logo

Treating Metastatic Bladder Cancer

03.02.2021

For patients with metastatic bladder cancer who are ineligible for cisplatin-containing chemotherapy and have high PD-L1 expression, atezolizumab and pembrolizumab are approved by the U.S. Food and Drug Administration (FDA) as first-line treatment. Multiple assays, which differ in terms of the antibodies used, cells scored, and cutoff values, are commercially available to assess PD-L1 expression. Because of the lack of standardization across these different tests, there is ambiguity surrounding the preferred assay for patients with metastatic bladder cancer.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor

03.02.2021

On 28 January 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product selinexor (Nexpovio) intended for the treatment of relapsed and refractory multiple myeloma.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib

01.02.2021

On 28 January 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product pemigatinib, intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma characterised by fusion or rearrangements of fibroblast growth factor receptor 2 (FGFR2).

asco logo

New ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment

29.01.2021

ASCO has released a new guideline regarding the use of neoadjuvant chemotherapy, endocrine therapy, and targeted therapy in breast cancer.

asco logo

ASCO Publishes Guideline Endorsement of ASTRO Guideline for Radiation Therapy in SCLC

28.01.2021

An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy (RT) for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.

asco logo

Investigating the Benefit of Neoadjuvant Over Adjuvant Therapy for Resectable Pancreatic Cancer

28.01.2021

The management of pancreatic ductal adenocarcinoma (PDAC) has undergone a major paradigm shift in the last 30 years. Before the 1990s, surgical resection was the main treatment modality, with high morbidity and slim chances for cure. In 1985, the Gastrointestinal Tumor Study Group demonstrated the benefit of adjuvant 5-fluorouracil-based chemoradiotherapy (CRT) with almost doubled median overall survival.

Aspiryna - ilistracja poglądowa

Korzyści z przyjmowania aspiryny w profilaktyce raka jelita grubego u osób starszych

28.01.2021

Wiadomo, że regularne stosowanie aspiryny przynosi wyraźne korzyści w zmniejszaniu zachorowalności na raka jelita grubego u dorosłych w średnim wieku, ale wiąże się również z pewnym ryzykiem, takim jak krwawienie z przewodu pokarmowego. W tym kontekście pojawia się ważne pytanie - kiedy dorośli powinni zacząć przyjmować profilaktycznie aspirynę i jak długo to robić?

asco logo

Organ preservation possible for most patients with early or locally advanced rectal cancer

26.01.2021

An early look at the data from the phase III OPERA (Organ Preservation in Early Rectal Adenocarcinoma) trial suggests that most patients with cT2, cT3a, or cT3b rectal cancer who develop a clinical complete response to treatment, may safely forego surgery after neoadjuvant chemoradiotherapy (CRT) plus an additional radiotherapy boost without compromising the chance of cure.

asco logo

Blood-based assay sparks hope for improving early detection and prevention of colorectal cancer

26.01.2021

A blood test for early detection of colorectal adenomas and cancer shows promise for improving survival and prevention of colorectal cancer (CRC) by enabling the stratification of patients for screening or post-polypectomy surveillance colonoscopy, according to a new study.

asco logo

Updated results from IMbrave150 underscore the benefit of frontline Atezolizumab plus Bevacizumab in unresectable HCC

26.01.2021

Results from the phase III IMbrave150 trial collected over a median of 15.6 months continue to support the superiority of combined treatment with atezolizumab plus bevacizumab over sorafenib in the first-line setting among individuals with unresectable hepatocellular carcinoma (HCC).

asco logo

Analysis of the PDAC immune microenvironment sheds light on the effects of chemotherapy, informing future treatment strategies

26.01.2021

An exploratory study reveals that neoadjuvant chemotherapy alters the immune microenvironment within pancreatic ductal adenocarcinoma (PDAC), and different chemotherapy regimens appear to exert different effects. Digging into the details of these data may help researchers determine how best to utilize chemotherapy in PDAC to maximize its efficacy.

esmo logo

FDA approves Nivolumab plus Cabozantinib for advanced renal cell carcinoma

25.01.2021

FDA approved the combination of nivolumab and cabozantinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Efficacy was evaluated in CHECKMATE-9ER (NCT03141177), a randomised, open-label study in patients with previously untreated advanced RCC.

program certyfikacji żywieniowej - baner

Szpitale stosujące dobre praktyki żywienia klinicznego - rusza II edycja programu certyfikacji żywieniowej

21.01.2021

Polskie Towarzystwo Żywienia Pozajelitowego, Dojelitowego i Metabolizmu (POLSPEN) rozpoczyna II edycję programu Szpital Dobrej Praktyki Żywienia Klinicznego – Leczenie przez żywienie. W pierwszej edycji udział wzięły 64 szpitale z całej Polski. Rada ekspertów, po przeprowadzeniu certyfikacji nagrodziła 27 szpitali. Pokazuje to, że jest jeszcze wiele obszarów do poprawy w zakresie żywienia klinicznego w polskim szpitalnictwie. Inicjatywa programu ma na celu upowszechnić w szpitalach dobre praktyki żywienia klinicznego i dać szansę pacjentom na poprawę stanu odżywienia podczas walki z chorobą.

esmo logo

Risk tool predicts severe chemotherapy toxicity in elderly patients with early breast cancer

21.01.2021

Cancer and Aging Research Group-Breast Cancer score, which they derived by combining eight clinical and geriatric variables, was developed to classify elderly patients with early breast cancer into low, intermediate, and high risk for developing grade 3-5 chemotherapy toxicity.

Miesiąc Radiologii Polskiej

Trwa „Miesiąc Radiologii Polskiej”

20.01.2021

Młodzi polscy lekarze i studenci medycyny zrzeszeni w organizacji RÉSONNEZ zapraszają na cykl webinarów poświęconych radiologii. Łącznie odbędzie się 12 sesji obejmujących tematykę m.in. diagnostyki radiologicznej raka piersi, RTG klatki piersiowej, radiologii interwencyjnej czy rozpoznawania złamań na obrazach rentgenowskich.

esmo logo

FDA approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive gastric adenocarcinomas

20.01.2021

FDA approved fam-trastuzumab deruxtecan-nxki for adult patients with locally advanced or metastatic HER2-positive gastric or gastro-oesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

esmo logo

GENIE registry identifies cancer types enriched with KRASG12C somatic mutations

18.01.2021

Findings from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry show that KRASG12C somatic mutations are present in non-small cell lung cancer (NSCLC), colorectal cancer, appendiceal and small bowel cancers, and cancers of unknown primary site, with a mutation frequency of 3 to 14%.

asco logo

ctDNA emerges as an early harbinger of postsurgical recurrence in patients with stage I-III CRC

16.01.2021

Serial analysis of circulating tumor DNA (ctDNA) after surgery can identify patients with stage I-III colorectal cancer (CRC) at high risk for recurrence. A prospective study demonstrated that ctDNA can signal relapse far better than carcinoembryonic antigen (CEA) surveillance and earlier than standard radiological imaging.

asco logo

Neoadjuvant mFOLFIRINOX established as reference standard in borderline resectable PDAC

16.01.2021

Patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX) had an 18-month overall survival (OS) rate of 66.4% in a prospective phase II study conducted by the National Clinical Trials Network (Abstract 377). This rate exceeded the prespecified historical control of 50%, establishing mFOLFIRINOX as efficacious.

asco logo

Updated 3-year results confirm the benefit of adjuvant S-1 plus Docetaxel for stage III gastric cancer

15.01.2021

The randomized controlled GC-07 trial conducted by the Japan Clinical Cancer Research Organization (JACCRO) previously met the primary endpoint at the second interim analysis by demonstrating a recurrence-free survival (RFS) advantage with use of S-1 plus docetaxel versus S-1 alone after D2 gastrectomy for stage III gastric cancer.1 As a result, the study was terminated as per the recommendation of the independent data and safety monitoring committee well before the overall survival (OS) data had fully matured.

rak jajnika - ilustracja poglądowa

Nowe perspektywy leczenia raka jajnika

15.01.2021

Leczenie zaawansowanego raka jajnika inhibitorami PARP, nowo zarejestrowanymi w Unii Europejskiej do stosowania po pierwszej linii leczenia, jest szansą na terapię tą innowacyjną grupą leków nie tylko chorych z mutacją w genach BRCA, ale i pozostałej większości pacjentek. Badania wykazały wydłużenie czasu wolnego od progresji choroby u wszystkich pacjentek chorych na raka jajnika, które odpowiedziały na chemioterapię pochodnymi platyny.

asco logo

Adding FGFR2b-targeted therapy to chemotherapy improved clinical outcomes for patients with advanced gastric-esophageal cancers in phase II study

15.01.2021

The phase II FIGHT study lays the groundwork for introducing another targeted therapy besides trastuzumab as a first-line treatment option for selected patients with advanced gastric or gastroesophageal junction adenocarcinoma (Abstract 160).

esmo logo

Adjuvant therapy with Oxaliplatin added to Fluoropyrimidine improves survival in patients with MSI/dMMR stage III colon cancer

15.01.2021

The ACCENT database analysis supports flouropyrimidine plus oxaliplatin as standard-of-care adjuvant treatment for patients with MSI/dMMR stage III colon cancer.

asco logo

The gut microbiome offers clues to immunotherapy efficacy in advanced gastric cancer

15.01.2021

Findings from the observational DELIVER trial sponsored by the Japan Clinical Cancer Research Organization showed that patients with advanced gastric cancer who responded to nivolumab treatment had a more diverse gut microbiome compared with patients who did not respond to the immunotherapy (Abstract 161).

esmo logo

Newly developed RSClin provides prognostic information in HR-positive, HER2-negative early breast cancer

14.01.2021

The online RSClin tool incorporating clinical-pathological data and the results of a 21-gene recurrence score (RS) was able to estimate the risk of distant recurrence (DR) and the benefit from adjuvant chemotherapy in specific patients with early breast cancer. The development and validation of this tool were outlined in an article appearing on 11 December 2020 in the Journal of Clinical Oncology.

esmo logo

Chemotherapy administered for the first diagnosed testicular cancer reduces the risk of metachronous contralateral testicular cancer occurrence

13.01.2021

Patients aged less than 30 years upon diagnosis of testicular cancer and those treated with surgery only are at higher risk of developing a metachronous contralateral (second) germ cell testicular cancer, according to a recent article published in the Journal of Clinical Oncology.

esmo logo

Palbociclib plus Endocrine therapy does not improve PFS over Capecitabine in HR-positive, HER2-negative aromatase inhibitor resistant metastatic breast cancer

12.01.2021

Although patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, aromatase inhibitor resistant metastatic breast cancer maintained quality of life (QoL) for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy demonstrated improved progression-free survival (PFS) and higher response rates compared with the palbociclib-treated patients.

asco logo

Circulating tumor DNA detection post-surgery foreshadows disease relapse in patients with early colorectal cancer

12.01.2021

Prospective data from the ongoing TRACC (Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer) trial in the United Kingdom support the prognostic utility of circulating tumor DNA (ctDNA) detection for heralding disease recurrence in patients with stage II/III colorectal cancer.

esmo logo

Prognostic value of longitudinal ctDNA assessment in oesophageal cancer

11.01.2021

In a multicentre, prospectively collected study in UK among operable patients with oesophageal cancer, the Oesophageal Cancer Classification and Molecular Stratification (OCCAMS) Consortium investigators demonstrated that the presence of ctDNA in post-operative plasma is strongly associated with cancer recurrence.

asco logo

Using short-course radiotherapy for patients with rectal cancer

11.01.2021

Management of rectal cancer needs a multidisciplinary approach to determine and deliver the most appropriate therapy for each patient. Short-course radiation followed by chemotherapy showed that complete pathologic response rates were possible for some patients. In addition, induction with mFOLFIRINOX therapy followed by chemoradiotherapy also afforded pathologic complete response rates higher than those seen historically. Is it then reasonable to consider the watch-and-wait strategy for those patients who desire organ preservation?

esmo logo

FDA approves Selinexor for refractory or relapsed multiple myeloma

08.01.2021

FDA approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Efficacy of selinexor in combination with bortezomib and dexamethasone was evaluated in the BOSTON study (KCP-330-023, NCT03110562), a randomised (1:1) open-label, multicentre, active comparator-controlled study in patients with RRMM who had previously received at least one and at most three prior therapies.

asco logo

Patient selection and sequencing therapeutics for microsatellite instability–high, mismatch repair–deficient metastatic colorectal cancer

08.01.2021

KEYNOTE-177 is the largest trial to date looking at checkpoint inhibitor immunotherapy (IO) with PD-1 inhibitor compared with chemotherapy in patients with MSI-high, mismatch repair (MMR)–deficient mCRC. Despite overall positive survival outcomes favoring IO, the Kaplan-Meier curve for the first 6 months of progression-free survival (PFS) highlights a subgroup of patients with MSI-high disease that progresses rapidly on IO monotherapy.

esmo logo

FDA approves Relugolix for advanced prostate cancer

07.01.2021

FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer. Efficacy was evaluated in HERO (NCT03085095), a randomised, open label study in men requiring at least one year of androgen deprivation therapy with either prostate cancer recurrence following radiation or surgery or newly diagnosed castration-sensitive advanced prostate cancer.

jelito grube - ilustracja poglądowa

Potrójna chemioterapia poprawia wyniki leczenia w przerzutowym raku jelita grubego

07.01.2021

Naukowcy z SWOG Cancer Research Network, grupy badań klinicznych finansowanej przez National Cancer Institute (NCI), wykazali, że połączenie trzech leków - irynotekanu, cetuksymabu i wemurafenibu - jest skuteczniejsze i zapewnia dłuższy czas wolny od nawrotu choroby u pacjentów z przerzutowym rakiem jelita grubego w porównaniu do pacjentów leczonymi połączeniem irynotekanu i cetuksymabu.

esmo logo

FDA approves Osimertinib as adjuvant therapy for NSCLC with EGFR malfunctions

05.01.2021

FDA approved osimertinib for adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Efficacy was demonstrated in a randomised, double-blind, placebo-controlled study (ADAURA, NCT02511106).

esmo logo

FDA approves Margetuximab for metastatic HER2-positive breast cancer

04.01.2021

FDA approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Efficacy was evaluated in SOPHIA (NCT02492711), a randomised, multicentre, open-label study of 536 patients with IHC 3+ or ISH-amplified HER2-positive metastatic breast cancer who had received prior treatment with other anti-HER2 therapies.

Obserwuj Onkonet na Facebooku

Preparat Nutridrink do leczenia żywieniowego firmy Nutricia

preparat do leczenia żywieniowego Nutridrink firmy Nutricia